Analysis

Roivant Sciences Ltd. (ROIV) Stock Analysis

Roivant Sciences Ltd. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to ROIV.

websiteROIV/analysis/ROIV

Roivant Sciences Ltd.

Roivant Sciences Ltd. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to ROIV.

Stock profile

Ticker

ROIV

Asset type

Stock

Market cap

$21.61B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Roivant Sciences Ltd. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • ROIV primary listing
  • 87S
  • A3C4MS

Latest Roivant Sciences Ltd. news

Roivant Sciences : Annual Report for Fiscal Year Ending March 31, 2025 (Form 10-K)

Roivant Sciences : Annual Report for Fiscal Year Ending March 31, 2025 (Form

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumato...

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday,...

BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 ...

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study ...

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound

Research sections

Valuation

Review valuation context for Roivant Sciences Ltd..

Future growth

Review future growth context for Roivant Sciences Ltd..

Past performance

Review past performance context for Roivant Sciences Ltd..

Financial health

Review financial health context for Roivant Sciences Ltd..

Dividend

Review dividend context for Roivant Sciences Ltd..

Management

Review management context for Roivant Sciences Ltd..

Ownership

Review ownership context for Roivant Sciences Ltd..

Other information

Review other information context for Roivant Sciences Ltd..

Community

Review community context for Roivant Sciences Ltd..